- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05031520
PericOronary INflammaTion in Non-Obstructive Coronary Artery Disease (POINT-NOCAD)
May 1, 2024 updated by: NYU Langone Health
A Single Center Study of Perivascular Coronary Inflammation in Patients With Myocardial Ischemia or Infarction With Non-Obstructive Coronary Arteries
Among patients with ischemic heart disease who are referred for coronary angiography, a substantial proportion have non-obstructive coronary artery disease (CAD).
Myocardial infarction (MI) with non-obstructive coronary artery disease (MINOCA) accounts for 5-20% of patients with MI and preferentially affects women.
MINOCA pathogenesis is varied and may include atherosclerotic plaque rupture, plaque erosion with thrombosis, vasospasm, embolization, dissection or a combination of mechanisms.
Other patients may have clinically unrecognized myocarditis, or takotsubo syndrome masquerading as MI.
Among patients referred for coronary angiography for the evaluation of stable ischemic heart disease, non-obstructive CAD is present in up to ~30% of men and ~60% of women.
Stable ischemia with non-obstructive coronary arteries (INOCA) may be due to coronary microvascular dysfunction in up to 40% of these patients.
Our understanding of mechanisms of MINOCA and INOCA remain incomplete.
Coronary inflammation has been hypothesized as a potential mechanism contributing to coronary spasm in MINOCA and microvascular disease in INOCA.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The PericOronary INflammaTion in Non-Obstructive Coronary Artery Disease (POINT-NOCAD) study is a single-center diagnostic, observational study enrolling men and women with MINOCA or INOCA who are planned to undergo (or underwent) clinically indicated coronary angiography.
The research plan is to evaluate coronary inflammation, as measured by the perivascular coronary fat attenuation index from non-invasive coronary computed tomography angiography (CCTA), in patients with MINOCA and INOCA.
Study Type
Observational
Enrollment (Estimated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Nathaniel Smilowitz, MD
- Phone Number: 212-263-5656
- Email: Nathaniel.Smilowitz@nyulangone.org
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- Recruiting
- NYU Langone Health
-
Contact:
- Nathaniel Smilowitz, MD
- Phone Number: 212-263-5656
- Email: Nathaniel.Smilowitz@nyulangone.org
-
Principal Investigator:
- Nathaniel Smilowitz, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 125 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Adults presenting to the NYU Langone Health Tisch/Kimmel Cardiac Catheterization Laboratory or the Bellevue Cardiac Catheterization laboratory will be screened and approached for consent if the patient's treating provider is amenable to their participation in the research study and if the patient is eligible for enrollment based on the eligibility criteria prior to clinically indicated cardiac catheterization.
Description
Inclusion Criteria:
- Adult age ≥18 years referred for clinically indicated coronary angiography
- Stable ischemic heart disease OR acute myocardial infarction as the indication for coronary angiography
Exclusion Criteria:
Clinical Exclusion criteria:
- Estimated glomerular filtration rate < 45 mL/min
- History of allergic reaction to iodinated contrast media
- Pregnancy
Angiographic / Post-Cath Exclusion criteria:
- Obstructive CAD (≥50% luminal obstruction in ≥1 major epicardial coronary arteries by invasive coronary angiography)
- Allergic reaction to iodinated contrast media
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Intervention group
Participants will be identified by review of the cardiac catheterization laboratory schedule each day by the principal investigator, a co-investigator, or a research coordinator.
Participants with no obstructive CAD and completed microvascular testing will undergo a research CCTA.
|
Participants will undergo CCTA.
CCTA performed in this study will be technically identical to CCTA that is commonly performed in clinical practice, for which safety profiles are well defined.
Guidelines implemented by the National Institutes of Health Radiation Exposure Committee will be followed.
Major risks of CCTA include exposure to ionizing radiation, the requirement for intravenous catheter placement and contrast media administration, and side effects of beta-blockers and nitrates that may be used for vasodilation and heart rate control to optimize CCTA image quality.
CCTA requires intravenous catheter placement and the administration of iodinated contrast media (Isovue).
Medication to promote coronary vasodilation during the CCTA may be administered immediately prior to CCTA to optimize image quality
Medication to promote heart rate reduction during the CCTA may be administered immediately prior to CCTA to optimize image quality
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Perivascular coronary fat attenuation will be significantly greater in MINOCA patients compared with INOCA patients
Time Frame: Visit 1, Day 0
|
Images obtained from the CCTA will be used to calculate perivascular FAI, measured around the proximal left anterior descending artery and in the right coronary artery, in the proximal 10 to 50 mm of the vessel.
For each coronary vessel, will define the weighted mean attenuation of all adipose tissue-containing voxels (-190 to -30 Hounsfield units [HU]) located within a radial distance from the outer vessel wall equal to the diameter of the respective vessel.
|
Visit 1, Day 0
|
Perivascular coronary fat attenuation will be greater in INOCA patients with versus without coronary microvascular disease
Time Frame: Visit 1, Day 0
|
Images obtained from the CCTA will be used to calculate perivascular FAI, measured around the proximal left anterior descending artery and in the right coronary artery, in the proximal 10 to 50 mm of the vessel.
For each coronary vessel, will define the weighted mean attenuation of all adipose tissue-containing voxels (-190 to -30 Hounsfield units [HU]) located within a radial distance from the outer vessel wall equal to the diameter of the respective vessel.
|
Visit 1, Day 0
|
Perivascular coronary fat attenuation in patients with MINOCA will be greatest in the culprit coronary vessels with evidence of acute plaque disruption.
Time Frame: Visit 1, Day 0
|
Images obtained from the CCTA will be used to calculate perivascular FAI, measured around the proximal left anterior descending artery and in the right coronary artery, in the proximal 10 to 50 mm of the vessel.
For each coronary vessel, will define the weighted mean attenuation of all adipose tissue-containing voxels (-190 to -30 Hounsfield units [HU]) located within a radial distance from the outer vessel wall equal to the diameter of the respective vessel.
|
Visit 1, Day 0
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Nathaniel Smilowitz, MD, NYU Langone Health
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 12, 2021
Primary Completion (Estimated)
July 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
August 24, 2021
First Submitted That Met QC Criteria
August 31, 2021
First Posted (Actual)
September 2, 2021
Study Record Updates
Last Update Posted (Estimated)
May 2, 2024
Last Update Submitted That Met QC Criteria
May 1, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Coronary Artery Disease
- Myocardial Ischemia
- Inflammation
- Atherosclerosis
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Nitroglycerin
- Metoprolol
Other Study ID Numbers
- 21-00764
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
IPD Sharing Time Frame
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
IPD Sharing Access Criteria
The investigator who proposed to use the data.
Upon reasonable request.
Requests should be directed to Nathaniel.Smilowitz@nyulangone.org.
To gain access, data requestors will need to sign a data access agreement.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Obstructive Coronary Atherosclerosis
-
Radboud University Medical CenterUMC Utrecht; Catharina Ziekenhuis Eindhoven; Noordwest Ziekenhuisgroep; Medical... and other collaboratorsEnrolling by invitationCoronary Vasospasm | Coronary Microvascular Dysfunction | Non-Obstructive Coronary AtherosclerosisNetherlands
-
Cedars-Sinai Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingIschemia | Coronary Artery Disease | Non-Obstructive Coronary AtherosclerosisUnited States
-
Eva Rumiz GonzálezHospital Clinic of Barcelona; Hospital General Universitario Elche; Hospital... and other collaboratorsRecruitingIschemia | Coronary Disease | Non-Obstructive Coronary AtherosclerosisSpain
-
AHEPA University HospitalUniversity of Zurich; New York UniversityCompletedAngina Pectoris | Ischemic Heart Disease | Coronary Microvascular Disease | Acute Myocardial Infarction | Non-Obstructive Coronary AtherosclerosisGreece
-
Guangdong Provincial People's HospitalCompletedNon-Obstructive Coronary AtherosclerosisChina
-
Aarhus University HospitalVejle Hospital; Aalborg University Hospital; Gødstrup Hospital; Hospital of South...RecruitingCoronary Artery Disease | Non-Obstructive Coronary AtherosclerosisDenmark
-
Istanbul UniversityCompletedIschemic Heart Disease | Coronary Microvascular Disease | Microvascular Angina | Coronary Microvascular Dysfunction | Non-Obstructive Coronary Atherosclerosis | Microvascular Coronary Artery DiseaseTurkey
-
NHS Greater Glasgow and ClydeAbbott Medical Devices; University of GlasgowRecruitingCoronary Artery Disease | Angina, Stable | Microvascular Angina | Vasospastic Angina | Coronary; Ischemic | Non-Obstructive Coronary Atherosclerosis | Ischemia With No Obstructive Coronary Arteries (INOCA) | Coronary Microvascular Dysfunction (CMD) | Ischaemic Heart Disease | Angina AttacksUnited Kingdom
-
NHS National Waiting Times Centre BoardBritish Heart Foundation; University of Glasgow; Chief Scientist Office of the...RecruitingCoronary Artery Disease | Angina, Stable | Angina Pectoris | Microvascular Angina | Non-Obstructive Coronary Atherosclerosis | Small Vessel Cerebrovascular DiseaseUnited Kingdom
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingMyocardial Infarction With Non-Obstructive Coronary Artery | Ischemia With Non-Obstructive Coronary ArteryItaly
Clinical Trials on Coronary computed tomography angiography (CCTA)
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Dutch Heart FoundationCompletedFamilial HypercholesterolemiaNetherlands
-
University of MichiganCompletedChest PainUnited States
-
Elsie NguyenUnknown
-
HeartFlow, Inc.Case Western Reserve UniversityCompletedCoronary Artery DiseaseDenmark
-
Central Clinical Hospital of the Russian Academy...Ural State Medical University; De Haar Research Task Force; De Haar Research... and other collaboratorsTerminatedCoronary Artery Disease | Alzheimer Disease | Contrast-induced Nephropathy | Coronary Atherosclerosis | Cerebrovascular Disease | Stable Chronic Angina | Chronic Coronary InsufficiencyNetherlands, Russian Federation, Estonia
-
Jordan Collaborating Cardiology GroupCompleted
-
Hemolens Diagnostics Sp. z o.o.GENELYTICA Sp. z o.o.CompletedCoronary Artery Disease | Stable Ischemic Heart DiseasePoland
-
Seoul National University Bundang HospitalCompletedDiabetes Mellitus | Coronary AtherosclerosisKorea, Republic of
-
National University of Ireland, Galway, IrelandGE Healthcare; HeartFlow, Inc.RecruitingMyocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Vascular Diseases | Coronary Artery Disease | Coronary Disease | Arteriosclerosis | Arterial Occlusive DiseasesItaly, Belgium, Germany
-
Erasmus Medical CenterRecruitingCoronary Artery DiseaseNetherlands